MGX - Metagenomi, Inc. Common Stock

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.

52W High

$4.92

52W Low

$1.23

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

2.12

P/B (<3 favorable)

0.37

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

28.09%

Institutions (25–75% balanced)

19.30%

Shares Outstanding

37,533,100

Float

25,276,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

33,768,000

Gross Profit (TTM)

-63,301,000

EPS (TTM)

-2.33

Profit Margin (>10% good)

-2.58%

Operating Margin (TTM) (higher better)

-2.47%

ROE (TTM) (>15% strong)

-0.37%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.58

Momentum

Bearish momentum

Value

-0.0368

-0.0402

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025